Teva Pharmaceutical Industries
$39.31Change from previous close: −0.73%Absolute change: −$0.29
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $45.85B
- Enterprise value
- $59.05B
- P/E (trailing 12 months)
- 65.5
- Forward P/E
- 12.7
- PEG
- 0.71
- Price/book
- 5.91
- Price/sales
- 2.65
- EV/EBITDA
- 13.8
- EV/revenue
- 3.41
Profitability and growth
- Gross margin
- 52.5%
- Operating margin
- 4.0%
- Net margin
- 4.1%
- ROE
- 9.7%
- ROA
- 5.1%
- Revenue growth (year over year)
- -0.8%
Financial health
- Total cash
- $3.66B
- Total debt
- $16.89B
- Debt/equity
- 2.18
- Current ratio
- 0.88
- Quick ratio
- 0.46
Dividends
- Payout ratio
- 0.0%
- Ex-dividend date
- November 28, 2017
Analysts and estimates
- Average price target
- $46.29
- Median price target
- $47.00
- High price target
- $55.00
- Low price target
- $40.00
- Analysts with a price target
- 7
- Consensus
- Buy
- Forward EPS
- $3.08
- EPS estimate, current year
- $2.17
Shares and trading
- Beta
- 0.80
- Average volume
- 5.35M
- Shares outstanding
- 1.17B
- Float
- 1.09B
- Institutional ownership
- 23.0%
- Insider ownership
- 0.6%
- Short interest (% of float)
- 2.7%
- Short ratio (days)
- 57.4